245 related articles for article (PubMed ID: 2365668)
21. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
[TBL] [Abstract][Full Text] [Related]
22. The effects of trazodone on sleep disturbances induced by brofaromine.
Haffmans PM; Vos MS
Eur Psychiatry; 1999 Jun; 14(3):167-71. PubMed ID: 10572343
[TBL] [Abstract][Full Text] [Related]
23. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations.
Le Bon O; Murphy JR; Staner L; Hoffmann G; Kormoss N; Kentos M; Dupont P; Lion K; Pelc I; Verbanck P
J Clin Psychopharmacol; 2003 Aug; 23(4):377-83. PubMed ID: 12920414
[TBL] [Abstract][Full Text] [Related]
24. [The effectiveness of treatment with trazodone in patients with primary insomnia without and with prior history of hypnotics use].
Wichniak A; Wierzbicka A; Sobańska A; Szatkowska E; Czasak K; Musińska I; Jernajczyk W
Pol Merkur Lekarski; 2007 Jul; 23(133):41-6. PubMed ID: 18051828
[TBL] [Abstract][Full Text] [Related]
25. Patients with insomnia and subthreshold depression show marked worsening of insomnia after discontinuation of sleep promoting medication.
Wichniak A; Wierzbicka A; Jernajczyk W
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1671-6. PubMed ID: 21723905
[TBL] [Abstract][Full Text] [Related]
26. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients.
Saletu-Zyhlarz GM; Anderer P; Arnold O; Saletu B
Neuropsychobiology; 2003; 48(4):194-208. PubMed ID: 14673218
[TBL] [Abstract][Full Text] [Related]
27. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
28. Adverse consequences of fluoxetine-MAOI combination therapy.
Feighner JP; Boyer WF; Tyler DL; Neborsky RJ
J Clin Psychiatry; 1990 Jun; 51(6):222-5. PubMed ID: 2347858
[TBL] [Abstract][Full Text] [Related]
29. Trazodone for antidepressant-associated insomnia.
Nierenberg AA; Adler LA; Peselow E; Zornberg G; Rosenthal M
Am J Psychiatry; 1994 Jul; 151(7):1069-72. PubMed ID: 8010365
[TBL] [Abstract][Full Text] [Related]
30. Trazodone: alternative dose regimens and sleep.
Wheatley D
Pharmatherapeutica; 1984; 3(9):607-12. PubMed ID: 6374681
[TBL] [Abstract][Full Text] [Related]
31. Rational polypharmacy in the bipolar affective disorders.
Post RM; Ketter TA; Pazzaglia PJ; Denicoff K; George MS; Callahan A; Leverich G; Frye M
Epilepsy Res Suppl; 1996; 11():153-80. PubMed ID: 9294735
[TBL] [Abstract][Full Text] [Related]
32. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression.
van Moffaert M; de Wilde J; Vereecken A; Dierick M; Evrard JL; Wilmotte J; Mendlewicz J
Int Clin Psychopharmacol; 1995 Mar; 10(1):3-9. PubMed ID: 7622801
[TBL] [Abstract][Full Text] [Related]
33. Long-term therapy for depression with trazodone.
Fabre LF; Feighner JP
J Clin Psychiatry; 1983 Jan; 44(1):17-21. PubMed ID: 6337131
[TBL] [Abstract][Full Text] [Related]
34. Low-dose trazodone effective in insomnia.
Bon OL
Pharmacopsychiatry; 2005 Sep; 38(5):226. PubMed ID: 16189753
[No Abstract] [Full Text] [Related]
35. [Combined therapy with tricyclic and MAOI antidepressants in the treatment of resistant major depression].
Rosan TA; Mesones HL; Brengio F
Acta Psiquiatr Psicol Am Lat; 1994 Dec; 40(4):314-20. PubMed ID: 7484185
[TBL] [Abstract][Full Text] [Related]
36. [Elderly patients, classical monoamine oxidase inhibitors and intercurrent somatic diseases].
Oostervink F; Bouvy PF; Touw DJ
Ned Tijdschr Geneeskd; 2003 Oct; 147(40):1937-40. PubMed ID: 14574773
[TBL] [Abstract][Full Text] [Related]
37. Results of a brief survey on the prescribing practices for monoamine oxidase inhibitor antidepressants.
Clary C; Mandos LA; Schweizer E
J Clin Psychiatry; 1990 Jun; 51(6):226-31. PubMed ID: 2347859
[TBL] [Abstract][Full Text] [Related]
38. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
[TBL] [Abstract][Full Text] [Related]
39. Drugs for psychiatric disorders.
Med Lett Drugs Ther; 1983 May; 25(635):45-52. PubMed ID: 6843486
[No Abstract] [Full Text] [Related]
40. Trazodone addition for insomnia in venlafaxine-treated, depressed inpatients: a semi-naturalistic study.
Bertschy G; Ragama-Pardos E; Muscionico M; Aït-Ameur A; Roth L; Osiek C; Ferrero F
Pharmacol Res; 2005 Jan; 51(1):79-84. PubMed ID: 15519538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
